RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

 

Regulatory Focus™ > News Articles > Quality & Compliance: Demystifying CMC Regulatory Strategy for Biologics, Part 1

Quality & Compliance: Demystifying CMC Regulatory Strategy for Biologics, Part 1

Posted 01 September 2011 | By

Owing to the Biologics Price Competition and Innovation Act of 2009 that permits the US Food and Drug Administration (FDA) to pursue an abbreviated market approval pathway for biologics, along with industry projections that biologics may represent one in every four newly commercialized drugs in the future, much attention is focused on this class of pharmaceutical products.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe

Regulatory Focus™ is doing essential, non-biased journalism during this unprecedented time. We appreciate your support as we bring you the news and intelligence you need to make an impact on global healthcare.

Regulatory Focus™ provides the intelligence you need to impact global healthcare during this crisis. Thank you for your support.